A new CAR-T is cred­it­ed with a 'sur­pris­ing' im­pact in tiny study of ad­vanced liv­er can­cer — rais­ing hopes on sol­id tu­mors

A tiny study has pro­vid­ed the first glim­mer of hope that Eu­re­ka Ther­a­peu­tics’ CAR-T ther­a­py may work in sol­id tu­mors.

In a proof-of-con­cept study in­volv­ing six pa­tients with he­pa­to­cel­lu­lar car­ci­no­ma — the most preva­lent form of liv­er can­cer — re­searchers re­port­ed that one pa­tient had a com­plete re­sponse, which was main­tained at the sev­en-month check­up. Two oth­ers saw their tu­mors shrink.

These, the biotech em­pha­sizes, are pa­tients who have failed mul­ti­ple pri­or treat­ments.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN